Identification of two novel Chlorotoxin derivatives CA4 and CTX-23 with chemotherapeutic and anti-angiogenic...

Area of Science:

• Neuroscience
• Oncology
• Biochemistry

Background:

• Brain tumors, particularly gliomas, are aggressive with limited curative treatment options.
• Targeting glioma-specific chloride channels presents a promising therapeutic avenue.
• Chlorotoxin (CTX), a scorpion-derived peptide, effectively blocks these channels.

Purpose of the Study:

• To design and evaluate novel chlorotoxin (CTX) derivatives for enhanced anti-glioma activity.
• To assess the efficacy of these derivatives in inhibiting glioma cell proliferation, migration, and angiogenesis.
• To determine the safety profile of the novel derivatives against neural cells.

Main Methods:

• Design and synthesis of two new CTX derivatives (CA4, CTX-23) based on sequence alignment.
• In vitro assays for glioma cell proliferation, migration, and spheroid migration.
• Assessment of cytotoxicity against primary neurons and astrocytes.
• Ex vivo studies using VOGiM (Vibratome-Organotypic Glioma Microenvironment) to evaluate anti-tumor and anti-angiogenic effects.

Main Results:

• CA4 and CTX-23 significantly reduced glioma cell proliferation and migration.
• Both derivatives, along with CTX, altered cell morphology (diminished extensions, increased nuclear size).
• CA4 and CTX-23 demonstrated low toxicity to primary neurons and astrocytes.
• Ex vivo studies showed CTX and CA4 reduced tumor volume and exhibited anti-angiogenic properties by disrupting endothelial and angiogenic hotspots.

Conclusions:

• The novel CTX derivatives, CA4 and CTX-23, possess significant anti-glioma properties.
• These derivatives demonstrate efficacy in reducing tumor growth and angiogenesis.
• CTX and its derivatives represent a promising therapeutic strategy for brain tumors, particularly gliomas.